Management of Antiplatelet Agents in Patients with Hematuria

Introduction to Antiplatelet Therapy Management

• The American Heart Association recommends that patients on antiplatelet therapy with hematuria should not discontinue aspirin or clopidogrel unless active major bleeding is present 1
• The European Society of Cardiology suggests that the cardiovascular risk of stopping antiplatelet therapy often exceeds the bleeding risk, particularly in patients with recent acute coronary syndrome, stroke, or coronary stents 2, 3

Antiplatelet Management Algorithm

• The American College of Cardiology recommends continuing antiplatelet therapy during initial hematuria evaluation unless active major bleeding is present 1
• For patients on dual antiplatelet therapy, consider transitioning to single antiplatelet agent if beyond the mandatory DAPT period 5, 4
• The International Journal of Stroke suggests that if within mandatory DAPT window, continue both agents unless life-threatening bleeding occurs 4

Perioperative Management for Urologic Procedures

• The European Heart Journal recommends continuing aspirin and clopidogrel for elective cystoscopy or minor urologic procedures as bleeding risk is manageable 6
• For major urologic surgery, discontinue clopidogrel 5-7 days preoperatively 6, 4, 1

Gastrointestinal Protection Strategy

• The American Gastroenterological Association suggests prescribing proton pump inhibitor for all patients on antiplatelet therapy with hematuria, as they are at high risk for gastrointestinal bleeding 2, 3, 1

Special Populations

• The American Geriatrics Society recommends that advanced age is a major bleeding risk factor under antiplatelet therapy, and do not use clopidogrel loading doses in patients >75 years receiving fibrinolytic therapy 1
• The National Kidney Foundation suggests that severe renal impairment substantially increases hemorrhagic complications with any antiplatelet regimen 1